Possible Effect of Blonanserin Transdermal Patch on Antiemetic Control in Patients With Terminal Cancer with Refractory Nausea.

Background

Haloperidol is widely used for antiemetic control in advanced cancer. However, due to its limited administration methods (oral or injection), its management is frequently challenging in palliative home care. Recently, a blonanserin transdermal patch was developed as the first antipsychotic percutaneous agent.

Objectives

This study aimed to evaluate its effectiveness and safety for refractory nausea.

Methods

We conducted an observational study of 21 terminal cancer patients who had been initiated for refractory nausea in their homes.

Results

After its initiation, none of the patients experienced aggravated nausea, and the number of patients with severe nausea decreased dramatically (52.4% vs. 9.5%, p = 0.008). Of 16 patients without ascites, 12.5% had not improved their nausea, which was lower than in patients with ascites (80.0%).

Conclusions

Blonanserin transdermal patch has a possible effect on antiemetic control in cancer patients, and its efficacy might be particularly prominent in patients without ascites.